Similar Posts
Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer
This webinar was conducted on May 28th, 2022 discussing the role of Nimotuzumab in the treatment of locally advanced squamous cell…
Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials
Tokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in…
Patent Pending for “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in numerous countries
Application for patents with the title of “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” are…
Webinar – Treatment Optimization in Locally Advanced & Metastatic Pancreatic Cancer-Tailored Patient Approach with Targeted Therapy
Prof. Dr. Dirk Strumberg, Oncologist in Marien Hospital Herne, Germany
Webinar – Clinical Experience of Using Nimotuzumab in Nasopharyngeal Cancer
Speaker: Dr. dr. Andhika Rachman, Sp.Pd-KHOM from MRCCC Siloam Hospital Indonesia
New Marketing Authorization Approval in Cambodia for new indication of locally advanced unresectable or metastatic pancreatic cancer.
On 24 Sep 2019, Cambodia Ministry of Health approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for…
